Why Cardinal Health Stock Was Tumbling on Tuesday

Cardinal Health (CAH) reported mixed fiscal Q4 2025 results, with revenue flat at $60.2 billion, missing analyst estimates, but non-GAAP net income rising 11% to $2.08 per share, exceeding expectations. Concurrently, the company announced a $1.9 billion cash acquisition of a 75% stake in Solaris Health, a leading urology multiservices organization, financed by cash on hand and new debt to bolster its Specialty Alliance. Despite raising its fiscal 2026 adjusted EPS guidance to $9.30-$9.50, CAH shares declined nearly 7% on the news, indicating market concern primarily over the sizable acquisition.

Analysis

Cardinal Health (CAH) presented a mixed operational and strategic update, resulting in significant negative market reaction. Operationally, the company's fiscal fourth-quarter 2025 results showed a divergence between top-line performance and profitability; revenue was flat year-over-year at approximately $60.2 billion, missing analyst consensus of $60.9 billion, while non-GAAP adjusted earnings per share rose 11% to $2.08, beating the $2.03 estimate. Despite this earnings beat and an upward revision of its full-year fiscal 2026 adjusted EPS guidance to a range of $9.30-$9.50, the market responded with a nearly 7% decline in the share price. This reaction appears primarily driven by the concurrent announcement of a major strategic move: the acquisition of a 75% stake in Solaris Health for roughly $1.9 billion. The deal, intended to bolster the company's urology specialty platform, will be financed with cash and new debt, signaling an increase in leverage that likely spooked investors. The market's negative sentiment (-0.6 score for CAH) indicates that concerns over the acquisition's price and the added debt are currently outweighing the positive signals from improved profitability guidance.

Key Decisions for Investors

• Investors should scrutinize the financial implications of the $1.9 billion Solaris Health acquisition, particularly the impact of new debt on the balance sheet, as this appears to be the primary driver of the stock's negative performance.
• Consider the divergence between the company's flat revenue growth and its rising profitability; the raised EPS guidance for fiscal 2026 is a positive, but long-term value depends on whether top-line growth can be reignited or if gains are purely from efficiency.
• Evaluate if the nearly 7% share price drop represents an overreaction, creating a potential entry point for those confident in the long-term strategic rationale of the Solaris deal and management's ability to integrate it effectively despite the market's initial skepticism.